title: [Impacts of stroke clinics on the utilization of statins for secondary prevention of ischemic stroke].
abstract: OBJECTIVE
  To describe the impact of stroke clinic on the usage of statins for secondary prevention of ischemic stroke.
  
  
  METHODS
  Data about the demography, social economic status, personal histories, blood lipid profiles, and the status of the usage of statins from 568 serial ischemic stroke patients were retrospectively analysed.
  
  
  RESULTS
  A total of 51.3% patients followed up in stroke clinic (306 patients) and 7.6% patients followed up in general clinic (262 patients) were treated with statins. 71.6% patients with and 44.8% patients without hyperlipidemia in stroke clinics were taking statins, which were higher than that patients in the general clinics (27.1% and 2.0% respectively). The patients in the stroke clinics with high LDL-C level (>3.4 mmol/L) were more likely to be treated with statins than those with lower level (25.6% vs 14.7%, P=0.017).
  
  
  CONCLUSIONS
  The rate of statins usage is extremely low in stroke patients followed up in a general clinic, but it can been improved greatly in a stroke clinic. Stroke clinic can narrow the gap between the clinical practice and the guideline for secondary prevention of ischemic stroke.
authors.affiliation: Department of Neurology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China.
authors.forename: Bei-li
authors.initials: BL
authors.lastname: Shao
authors.forename: Jie-li
authors.initials: JL
authors.lastname: Geng
authors.forename: Yan-sheng
authors.initials: YS
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D004363:Drug Utilization; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D002546:Ischemic Attack, Transient / Q000188:drug therapy / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D055502:Secondary Prevention; D020521:Stroke / Q000188:drug therapy* / Q000517:prevention & control
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors